Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Aug 15, 2025; 16(8): 108310
Published online Aug 15, 2025. doi: 10.4239/wjd.v16.i8.108310
Rheb1 as a novel β-cell regulator connecting mTORC1, AMPK, and NOTCH1 pathways for efficient diabetes therapy
Mostafa M Gouda
Mostafa M Gouda, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou 310058, Zhejiang Province, China
Mostafa M Gouda, Department of Nutrition & Food Science, National Research Centre, Giza 12622, Egypt
Author contributions: Gouda MM contributed to conceptualization, methodology, literature search, figure building, and original draft writing and revision of this manuscript.
Supported by Zhejiang University Global Partnership Fund, No. BIO-0322023.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mostafa M Gouda, PhD, Professor, College of Biosystems Engineering and Food Science, Zhejiang University, No. 866 Yuhangtang Road, Hangzhou 310058, Zhejiang Province, China. mostafa-gouda@zju.edu.cn
Received: April 11, 2025
Revised: May 19, 2025
Accepted: July 14, 2025
Published online: August 15, 2025
Processing time: 126 Days and 1.2 Hours
Abstract

This editorial comments on the study by Yang et al, emphasizing the Ras homolog enriched in brain 1 (Rheb1) core function in restoring functional β-cell mass in diabetes, as crucial for β-cell proliferation and survival. It has been revealed that Rheb1 promotes β-cell regeneration through a dual pathway, activating mammalian target of rapamycin complex 1 and simultaneously inhibiting AMP-activated protein kinase (AMPK). Blocking mammalian target of rapamycin complex 1 while stimulating AMPK was necessary to halt β-cell expansion, challenging traditional single-target approaches. Rheb1 also supported β-cell identity by triggering neurogenic locus notch homolog protein 1 signaling and interacting with hepatocyte nuclear factor 4 alpha, linked to maturity-onset diabetes of the young 1. An age-related decline of Rheb1 in human islets suggests its role in diminished regenerative capacity in adulthood. These findings make Rheb1 a promising therapeutic target for rejuvenating β-cells by linking nutrient sensing and energy regulation. Focusing on Rheb1 could alter diabetes treatment, merging proliferation with identity preservation for next-generation therapies. The gaps and translational opportunities, from Rheb1 modulators to biomarkers, were emphasized, advocating for interdisciplinary collaboration to maximize this pathway for positive clinical outcomes. Additional studies are needed to thoroughly investigate AMPK’s involvement in the Rheb1 metabolic biomarker associated with brain health and its possible therapeutic benefits.

Keywords: Ras homolog enriched in brain 1; Β-cell proliferation; Maturity-onset diabetes of the young 1; Diabetes therapy; Metabolic regulation; Pancreatic islets; Insulin secretion

Core Tip: This editorial emphasizes the critical role of β-cells in diabetes risk, particularly regarding brain dysfunction and ulceration in young individuals, and underscores the need for further investigation. Recent studies, including that of Yang et al, demonstrate the key influence of Ras homolog enriched in brain 1 on β-cell function and proliferation, which is linked to insulin secretion and glucose levels. This suggests that Ras homolog enriched in brain 1 influences the mammalian target of rapamycin complex 1 and AMP-activated protein kinase pathways, confirming the existence of the islet reflex instead of relying solely on one pathway. This metabolic role opens up therapeutic avenues for advanced treatment targets of diabetes-related brain dysfunction.